Literature DB >> 35474549

Demographics, clinical characteristics and cognitive symptoms of heavy smokers and non-heavy smokers in Chinese male patients with chronic schizophrenia.

Shuochi Wei1,2, Dongmei Wang1,2, Huixia Zhou1,2, Luyao Xia1,2, Yang Tian1,2, Qilong Dai1,2, Rongrong Zhu1,2, Wenjia Wang1,2, Dachun Chen3, Meihong Xiu3, Li Wang1,2, Xiangyang Zhang4,5.   

Abstract

Many studies have shown a high smoking rate and cognitive impairment in patients with schizophrenia. The effects of smoking and nicotine intake on cognitive function in schizophrenia are still controversial. In this study, we divided patients into heavy smoking and non-heavy smoking groups and compared the clinical characteristics and cognitive symptoms between the two groups in Chinese male patients with schizophrenia. A total of 154 heavy smoking patients and 372 non-heavy smoking patients were recruited. They completed a detailed questionnaire including general and socio-demographic data. Positive and Negative Syndrome Scale (PANSS) was rated for psychopathology. The Fagerstrom Test for Nicotine Dependence (FTND) was used to assess the degree of nicotine dependence. Heavy smokers were younger, started smoking earlier and had a higher FTND total score than non-heavy smoking patients. Moreover, we found that heavy smokers had significantly lower negative symptom scores and cognitive factor scores than non-heavy smokers. Logistic regression analysis showed that cognitive factor score and age of initial smoking were significantly associated with heavy smoking. Linear regression analysis showed that cognitive factor score, age of initial smoking and dose of antipsychotics were significant predictors of the amount of smoking. Our findings suggest that there are significant differences in some demographic and clinical variables between heavy and non-heavy smokers in Chinese male patients with chronic schizophrenia. Moreover, heavy smokers have less cognitive symptoms, suggesting that heavy smoking may be beneficial for cognition of patients with schizophrenia.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Cognitive Symptoms; Nicotine; Schizophrenia; Smoking

Year:  2022        PMID: 35474549     DOI: 10.1007/s00406-022-01410-y

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.760


  58 in total

1.  Chronic tobacco smoking and neuropsychological impairments: A systematic review and meta-analysis.

Authors:  A A Conti; L McLean; S Tolomeo; J D Steele; A Baldacchino
Journal:  Neurosci Biobehav Rev       Date:  2018-11-28       Impact factor: 8.989

2.  Schizophrenia, smoking status, and performance on the matrics Cognitive Consensus Battery.

Authors:  Alexandra C Reed; Josette G Harris; Ann Olincy
Journal:  Psychiatry Res       Date:  2016-09-09       Impact factor: 3.222

Review 3.  The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis.

Authors:  Anne-Kathrin J Fett; Wolfgang Viechtbauer; Maria-de-Gracia Dominguez; David L Penn; Jim van Os; Lydia Krabbendam
Journal:  Neurosci Biobehav Rev       Date:  2010-07-08       Impact factor: 8.989

4.  Cognitive function in schizophrenia: conflicting findings and future directions.

Authors:  Ahmed A Moustafa; Julia K Garami; Justin Mahlberg; Jan Golembieski; Szabolcs Keri; BlaŻej Misiak; Dorota Frydecka
Journal:  Rev Neurosci       Date:  2016-06-01       Impact factor: 4.353

Review 5.  Clinical picture, pathogenesis and psychometric assessment of negative symptoms of schizophrenia.

Authors:  Paweł Wójciak; Janusz Rybakowski
Journal:  Psychiatr Pol       Date:  2018-04-30       Impact factor: 1.657

Review 6.  Meta-analysis of functional magnetic resonance imaging studies of timing and cognitive control in schizophrenia and bipolar disorder: Evidence of a primary time deficit.

Authors:  Irene Alústiza; Joaquim Radua; Marta Pla; Raquel Martin; Felipe Ortuño
Journal:  Schizophr Res       Date:  2017-02-04       Impact factor: 4.939

Review 7.  Estrogens and the cognitive symptoms of schizophrenia: Possible neuroprotective mechanisms.

Authors:  Claire McGregor; Alexander Riordan; Janice Thornton
Journal:  Front Neuroendocrinol       Date:  2017-06-30       Impact factor: 8.606

8.  Cognitive Change in Schizophrenia and Other Psychoses in the Decade Following the First Episode.

Authors:  Jolanta Zanelli; Josephine Mollon; Sven Sandin; Craig Morgan; Paola Dazzan; Izabela Pilecka; Tiago Reis Marques; Anthony S David; Kevin Morgan; Paul Fearon; Gillian A Doody; Peter B Jones; Robin M Murray; Abraham Reichenberg
Journal:  Am J Psychiatry       Date:  2019-07-01       Impact factor: 19.242

9.  Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort.

Authors:  Anja P Husa; Jani Moilanen; Graham K Murray; Riikka Marttila; Marianne Haapea; Irina Rannikko; Jennifer H Barnett; Peter B Jones; Matti Isohanni; Anne M Remes; Hannu Koponen; Jouko Miettunen; Erika Jääskeläinen
Journal:  Psychiatry Res       Date:  2016-11-12       Impact factor: 3.222

10.  Smoking Rates and Number of Cigarettes Smoked per Day in Schizophrenia: A Large Cohort Meta-Analysis in a Japanese Population.

Authors:  Kazutaka Ohi; Takamitsu Shimada; Aki Kuwata; Yuzuru Kataoka; Hiroaki Okubo; Kohei Kimura; Toshiki Yasuyama; Takashi Uehara; Yasuhiro Kawasaki
Journal:  Int J Neuropsychopharmacol       Date:  2019-01-01       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.